Concepts of the pathogenesis of allergic disease: Possible roles of Epstein-Barr virus infection and interleukin-2 production

International Archives of Allergy and Immunology

Volumn 120, Issue 3, 1999, Pages 177-184

  Okudaira, Hirokazu ^a   Mori, Akio ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

Atopy; Eosinophilic inflammation; Epstein Barr virus; IgE; IL 5

Indexed keywords

INTERLEUKIN 2; ONCOPROTEIN;

ALLERGIC DISEASE; ATOPY; DEVELOPED COUNTRY; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; IMMUNOCOMPETENT CELL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

EID: 0032757739     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024265     Document Type: Review

References (83)

1. Okudaira H, Ishizaka K: Reaginic antibody formation in the mouse. XI. Participation of long-lived antibody-forming cells in persistent antibody formation. Cell Immunol 1981;58:188-201.
2. Ishizaka K, Ishizaka T: in Lichtenstein LM, Austen KF (eds): Asthma, Physiology, Immunopharmacology and Treatment. New York, Academic Press, 1973, pp 55.
3. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM: IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472-482.
4. Vaz EM, Vaz NM, Levine BB: Persistent formation of reagins in mice injected with low doses of ovalbumin. Immunology 1971;21:11-15.
5. Peeters SH, Carter BG: Regulation of the IgE antibody response in mice. I. Long-term production of IgE anti-ovalbumin antibody in irradiated recipients. J Immunol 1978;121:1596-1602.
6. Takatsu K, Ishizaka K, King TP: Immunogenic properties of modified antigen E. III. Effect of repeated injections of modified antigen on immunocompetent cells specific for native antigen. J Immunol 1975;115:1469-1476.
7. Nossal GJV, Ada GL: Antigens, Lymphoid Cells and the Immune Response. New York, Academic Press, 1971.
8. Britton S, Moller GJ: Regulation of antibody synthesis against Excherichia coli endotoxin. I. Suppressive effect of endogenously produced and passively transferred antibodies. J Immunol 1968;100:1326-1334.
9. Romball CG, Weigle WO: A cyclical appearance of antibody-producing cells after a single injection of serum protein antigen. J Exp Med 1973;138:1426-1442.
10. Kontiainen S, Mitchison NA: Blocking antigen-antibody complexes on the T-lymphocyte activation during in vitro incubation before adoptive transfer. Immunology 1975;28:523-533.
11. Tew JG, Self CH, Harold WW, Stavitsky AB: The spontaneous induction of anamnestic antibody synthesis in lymph node cell cultures many months after primary immunization. J Immunol 1973;111:416-423.
12. Gengozian N, Makinodan T: Relation of primary antigen injection to time of irradiation on antibody production in mice. J Immunol 1958; 80:189-197.
13. Dixon FJ, McConahey PJ: Enhancement of antibody formation by whole body X-radiation. J Exp Med 1963;117:833-847.
14. Mitchison NA: The carrier effect in the secondary response to hapten-protein conjugates. V. Use of antilymphocyte serum to deplete animals of helper cells. Eur J Immunol 1971;1:68-75.
15. Cunningham AJ, Sercarz EE: The asynchronous development of immunological memory in helper (T) and precursor (B) cell lines. Eur J Immunol 1972;1:413-421.
16. Kettman J, Dutton RW: Radioresistance of the enhancing effect of cells from carrier-immunized mice in an in vitro primary immune response. Proc Natl Acad Sci USA 1971;68:699-703.
17. Hamaoka T, Katz DH, Benacerraf B: Radioresistance of carrier-specific helper thymus-derived lymphocytes in mice. Proc Natl Acad Sci USA 1972;69:3453-3458.
18. Grobler P, Buerki H, Cottier H, Hess MW, Stoner RD: Cellular bases for relative radioresistance of the antibody-forming system at advanced stages of the secondary response to tetanus toxoid in mice. J Immunol 1974;112:2154-2165.
19. Danneman PJ, Michael JG: Regulation of reaginic antibody production in mice. I. Suppression by antigen of IgE antibody production in vitro. J Exp Med 1977;146:1534-1548.
20. Schooley JC: Autoradiographic observation of plasma cell formation. J Immunol 1961;86:331-337.
21. Nossal GJV, Mäkelä O: Autoradiographic studies on the immune response. J Exp Med 1962;115:209-230.
22. Miller JJ III: An autoradiographic study of plasma cell and lymphocyte survival in rat popliteal lymph nodes. J Immunol 1964;92:673-681.
23. Tjio AH, Hull WM, Gleich GJ: Production of human immunoglobulin E antibody in vitro. J Immunol 1979;122:2131-2133.
24. Takatsu K, Ishizaka K: Reaginic antibody formation in the mouse. VII. Depression of the ongoing IgE antibody formation by suppressor T cells. J Immunol 1976;117:1211-1218.
25. Liu YJ, Mason DY, Johnson GD, Abbot S, Gregory CD, Hardie DL, Gordon J, MacLennan IC: Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991;21:1905-1910.
26. Bothwell AL, Paskind M, Reth M, Imanishi-Kari T, Rajewsky K, Baltimore D: Heavy chain variable region contribution to the NPb family of antibodies: Somatic mutation evident in a gamma 2a variable region. Cell 1981;24:625-637.
27. Tonegawa S: Somatic generation of antibody diversity. Nature 1983;302:575-581.
28. Griffiths GM, Berek C, Kaartinen M, Milstein C: Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature 1984;312:271-275.
29. Berek C, Griffiths GM, Milstein C: Molecular events during maturation of the immune response to oxazolone. Nature 1985;316:412-418.
30. MacLennan IC, Gray D: Antigen-driven selection of virgin and memory B cells. Immunol Rev 1986;91:61-85.
31. MacLennan IC, Liu YJ, Ling NR: B cell proliferation in follicles, germinal centre formation and the site of neoplastic transformation in Burkitt's lymphoma. Curr Top Microbiol Immunol 1988;141:138-148.
32. Nieuwenhuis P, Opstelten D: Functional anatomy of germinal centers. Am J Anat 1984;170:421-435.
33. Fliedner TM, Kesse M, Cronkite EP, Robertson JS: Cell proliferation in germinal centers of the rat spleen. Ann NY Acad Sci 1964; 113:578-594.
34. Tew JG, Mandel T: The maintenance and regulation of serum antibody levels: Evidence indicating a role for antigen retained in lymphoid follicles. J Immunol 1978;120:1063-1069.
35. Tew JG, Mandel TE: Prolonged antigen half-life in the lymphoid follicles of specifically immunized mice. Immunology 1979;37:69-76.
36. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC: Mechanism of antigen-driven selection in germinal centres. Nature 1989;342:929-931.
37. Liu YJ, Cairns J, Holder MJ, Abbot S, Jansen KU, Bonnefoy JY, Gordon J, MacLennan IC: Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: Eevidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991;21:1107-1114.
38. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
39. Vaux DL, Cory S, Adams JM: Bcl-gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
40. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.
41. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
42. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the 1 (14;18). Nature 1991;349:254-256.
43. Levy Y, Brouet JC: IL-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994;93:424-428.
44. Hockenbery D, Nunez G, Millman C. Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
45. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886.
46. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-6965.
47. Burdin N, Péronne C, Banchereau J, Rousset F: Epstein-Barr virus (EBV) transformation induces B lymphocytes to produce human IL-10. J Exp Med 1993;177:295-304.
48. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, Lenoir GM: Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci USA 1987;84:8060-8064.
49. Lenoir GM, Bornkamm GW: Burkitt's lymphoma, a human cancer model for the study of multistep development of cancer: Proposal for a new scenario. Adv Viral Oncol 1987;7:173-178.
50. Benjamin D, Knobloch TJ, Dayton MA: Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992;80:1289-1298.
51. Klein G: Viral latency and transfomation: The strategy of Epstein-Barr virus. Cell 1989;58:5-8.
52. Tosato G: The Epstein-Barr virus and the immune system; in Klein G, Weinhouse S (eds): Advances in Cancer Research. London, Academic Press, 1987, pp 49-75.
53. Yao QY, Ogan P, Rowe M, Wool M, Rickinson AB: Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989;43:67-71.
54. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I: Eradication of Epstein-Barr virus by allogeneic marrow transplantation: Implications for sites of viral latency. Proc Natl Acad Sci USA 1988;85:8693-8696.
55. Mori A, Kaminuma O, Suko M, Inoue S, Ohmura T, Hoshino A, Asakura Y, Miyazawa K, Yokota T, Okumura Y, Ito K, Okudaira H: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 1997;8:2891-2900.
56. Okudaira H, Mori A: Simple understanding and optimistic strategy for coping with atopic diseases. Int Arch Allergy Immunol 1998;117: 11-19.
57. Jeffery PK, Waldlaw AJ, Nelson FC, Collins JV, Kay AB: Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140:1745-1753.
58. Gleich GJ, Adolphson CR: The eosinophilic leukocyte: Structure and function. Adv Immunol 1986;39:177-253.
59. Kay AB: 'Helper' (CD4+) T cells and eosinophils in allergy and asthma. Am Rev Respir Dis 1992;145:S22-S26.
60. Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ, Bradley B, Durham SR, Collins JV, Jeffery PK, Quint J, Kay AB: Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-1546.
61. Gulbenkian AR, Egan RW, Fernandez X, Jones H, Kreutner W, Kung T, Payvandi F, Sullivan L, Zurcher JA, Watnick AS: Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. Am Rev Respir Dis 1992; 146:263-266.
62. Mauser PJ, Pitman A, Witt A, Fernandez X, Zurcher J, Kung T, Jones H, Watnick AS, Egan RW, Kreutner W, Adams GK: Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993;148:1623-1627.
63. Robinson DS, Ying S, Bentley AM, Meng Q, North J, Durham SR, Kay AB, Hamid Q: Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol 1993;92:397-403.
64. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR: Activation of CD4+ T cells, increased TH2 type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993;92:313-324.
65. Ohnishi T, Kita H, Weiler D, Sur S, Sedgwick JB, Calhoun WJ, Busse WW, Abrams JS, Gleich GJ: IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis 1993;147:901-907.
66. Corrigan CJ, Haczku A, Gemou-Engesaeth V, Doi S, Kikuchi Y, Takastu K, Durham SR, Kay AB: CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis 1993;147:540-547.
67. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S, Kay AB: Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-γ cytokine gene expression. Am Rev Respir Dis 1993; 148:401-406.
68. Mori A, Suko M, Kaminuma O, Nishizaki Y, Mikami T, Ohmura T, Hoshino A, Inoue S, Tsuruoka N, Okumura Y, Sato G, Ito K, Okudaira H: A critical role of IL-2 for the production and gene transcription of IL-5 in allergen-specific human T cell clones. Int Immunol 1996;8:1889-1895.
69. Mori A, Suko M, Tsuruoka N, Kaminuma O, Ohmura T, Nishizaki Y, Ito K, Okudaira H: Allergen-specific human T cell clones produce IL-5 upon stimulation with Th1 cytokine, IL-2. Int Arch Allergy Immunol 1995;107:220-222.
70. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI: Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992;89:958-967.
71. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
72. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr: Allergic and nonallergic asthmatics have distinct patterns of T cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992;146:109-115.
73. Kay AB, Ying S, Varney V, Gaga M, Durham SR, Moqbel R, Wardlaw AJ, Hamid Q: Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5 and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775-778.
74. Straus SE, Cohen JI, Tosato G, Meier J: NIH Conference Epstein-Barr virus infections: Biology, pathogenesis, and management. Ann Intern Med 1993;118:45-58.
75. Straus SE, Fleisher GR: Infectious mononucleosis epidemiology and pathogenesis; in Schlossberg D (ed): Infectious Mononucleosis, ed 2. New York, Springer, 1989, pp 8-28.
76. Filatow NJ: Lektush ob ostriku infektsion Nikh Lolieznyak [Lectures on acute infectious diseases of children]. Moscow, U Deitel, 1885.
77. Okudaira H: Why atopic diseases prevail in developed countries. ACI Int 1988;10:110-115.
78. Rystedt I, Strannegard IL, Strannegard O: Increased serum levels of antibodies to Epstein-Barr virus in adults with history of atopic dermatitis. Int Arch Allergy Appl Immunol 1984; 75:179-183.
79. Strannegard IL, Strannegard O: Epstein-Barr virus antibodies in children with atopic disease. Int Arch Allergy Appl Immunol 1981; 64:314-329.
80. Strannegard O, Strannegard IL: T-lymphocyte numbers and function in human IgE-mediated allergy. Immunol Rev 1978;41:149-170.
81. Rackemann FM: A working classification of asthma. Am J Med 1947;3:601-606.
82. Lay JD, Tsao CJ, Chen JY, Marshall E, Kadin ME, Su IJ: Upregulation of tumor necrosis factor-α gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997;100:1969-1979.
83. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high affinity IgE receptor (FceRI) mediates IgE-dependent allergen presentation. J Immunol 1995;154:6285-6290.